A Multicenter Observational Retrospective Study of Second-Line Treatment With Daratumumab-Bortezomib-Dexamethasone (DaraVd) in Multiple Myeloma (MM) Patients Refractory to Lenalidomide

被引：0

作者：

Rizzello, Ilaria ^{[1
]}

Sacchetti, Ilaria ^{[1
]}

Barbato, Simona ^{[1
]}

Solli, Vincenza ^{[1
]}

Stefanoni, Paola ^{[2
]}

Cani, Lorenzo ^{[3
]}

Pavan, Laura ^{[4
]}

Quaresima, Micol ^{[5
]}

Belotti, Angelo ^{[6
]}

Sgherza, Nicola ^{[7
]}

Gentile, Massimo ^{[8
]}

Barila, Gregorio ^{[9
]}

Patriarca, Francesca ^{[10
]}

Celli, Melania ^{[11
]}

Vincelli, Iolanda Donatella ^{[12
]}

Mancuso, Katia ^{[1
]}

Sartor, Chiara ^{[1
]}

Pantani, Lucia ^{[1
]}

Tacchetti, Paola ^{[1
]}

Talarico, Marco ^{[1
]}

Puppi, Michele ^{[1
]}

Bigi, Flavia ^{[1
]}

Cavo, Michele ^{[1
]}

Zamagni, Elena ^{[1
]}

机构：

[1] IRCCS Azienda Osped Univ Bologna, Ist Ematol Seragnoli, Bologna, Italy

[2] ASST Papa Giovanni XXIII, Dept Oncol & Hematol, Bergamo, Italy

[3] AOU Citta Salute & Sci Torino, Div Hematol, Turin, Italy

[4] AOU Padova, Ematol, Padua, Italy

[5] AUSL Reggio Emilia, Ematol, Reggio Emilia, Italy

[6] ASST Spedali Civili Brescia, Dept Hematol, Brescia, Italy

[7] AOUC Policlin, Hematol, Bari, Italy

[8] AO Cosenza, Dept Oncohematol, Hematol Unit, Cosenza, Italy

[9] Osped San Bortolo, Ematol, Vicenza, Italy

[10] Azienda Sanit Univ Friuli Cent, Clin Ematol, Cosenza, Italy

[11] Osped Infermi Rimini, UO Ematol, Rimini, Italy

[12] GOM Bianchi Melacrino Morelli, UOC Ematol, Reggio Di Calabria, Italy

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-416

引用

页码：S275 / S275

页数：1

共 50 条

[41] Efficacy of ixazomib, lenalidomide, dexamethasone regimen in daratumumab-exposed relapsed/refractory multiple myeloma patients: A retrospective analysis
Fric, Dominik
Stork, Martin
Boichuk, Ivanna
Sandecka, Viera
Adam, Zdenek
Krejci, Marta
Ondrouskova, Eva
Fidrichova, Anna
Radova, Lenka
Knechtova, Zdenka
Jarosova, Marie
Pour, Ludek
EUROPEAN JOURNAL OF HAEMATOLOGY, 2024, 113 (06) : 810 - 816
[42] Phase II study of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with relapsed or relapsed and refractory multiple myeloma (MM)
Anderson, K. C.
Jagannath, S.
Jakubowiak, A.
Lonial, S.
Raje, N.
Schlossman, R.
Munshi, N.
Knight, R.
Esseltine, D.
Richardson, P. G.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[43] Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients - real world evidence analysis
Stork, Martin
Spicka, Ivan
Radocha, Jakub
Minarik, Jiri
Jelinek, Tomas
Jungova, Alexandra
Pavlicek, Petr
Pospisilova, Lenka
Sedlak, Frantisek
Straub, Jan
Pika, Tomas
Knechtova, Zdenka
Fidrichova, Anna
Boichuk, Ivanna
Sevcikova, Sabina
Maisnar, Vladimir
Hajek, Roman
Pour, Ludek
ANNALS OF HEMATOLOGY, 2023, 102 (06) : 1501 - 1511
[44] Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM) Patients: An Update of Overall Survival in Castor
Lentzsch, Suzanne
Quach, Hang
Chanan-Khan, Asher A.
Horvath, Noemi
Capra, Marcelo
Ovilla, Roberto
Jo, Jae-Cheol
Shin, Ho-Jin
Thiyagarajah, Piruntha
Amin, Himal
Casneuf, Tineke
Sonneveld, Pieter
Schecter, Jordan
Hungria, Vania T. M.
BLOOD, 2017, 130
[45] Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis
Martin Stork
Ivan Spicka
Jakub Radocha
Jiri Minarik
Tomas Jelinek
Alexandra Jungova
Petr Pavlicek
Lenka Pospisilova
Frantisek Sedlak
Jan Straub
Tomas Pika
Zdenka Knechtova
Anna Fidrichova
Ivanna Boichuk
Sabina Sevcikova
Vladimir Maisnar
Roman Hajek
Ludek Pour
Annals of Hematology, 2023, 102 : 1501 - 1511
[46] An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide plus dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR-MM)
Leleu, Xavier
Terpos, Evangelos
Garcia Sanz, Ramon
Cooney, Julian
O'Gorman, Peter
Minarik, Jiri
Greil, Richard
Williams, Catherine
Gray, Diep
Szabo, Zsolt
AMERICAN JOURNAL OF HEMATOLOGY, 2016, 91 (08) : 806 - 811
[47] AN INTERNATIONAL, MULTICENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF NEUTROPENIA IN PATIENTS BEING TREATED WITH LENALIDOMIDE plus DEXAMETHASONE FOR RELAPSED OR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RR-MM)
Leleu, X.
Terpos, E.
Garcia Sanz, R.
Cooney, J.
O'Gorman, P.
Minarik, J.
Greil, R.
Williams, C.
Gray, D.
Szabo, Z.
HAEMATOLOGICA, 2014, 99 : 368 - 368
[48] Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma
Shinsuke Iida
Tatsuo Ichinohe
Atsushi Shinagawa
Kenshi Suzuki
Naoki Takezako
Masayuki Aoki
International Journal of Hematology, 2018, 107 : 460 - 467
[49] COST-EFFECTIVENESS ANALYSIS OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (DRD) AND DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE (DVD) VERSUS STANDARD OF CARE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)
Pelligra, C.
Guo, S.
Parikh, K.
Zhang, S.
Krotneva, M.
Onyekwere, U.
Clancy, Z.
VALUE IN HEALTH, 2018, 21 : S254 - S254
[50] A prospective, multicenter, observational study of ixazomib plus lenalidomide-dexamethasone in 295 Japanese patients with relapsed/refractory multiple myeloma
Iino, Masaki
Horigome, Yuichi
Harazaki, Yoriko
Kobayashi, Takahiro
Handa, Hiroshi
Hiramatsu, Yasushi
Kuroi, Taiga
Tanimoto, Kazuki
Matsue, Kosei
Yoshida, Takahiro
Mori, Ikuo
Abe, Masahiro
Akagi, Kiwamu
Hayashi, Toshiaki
Ishida, Tadao
Ito, Shigeki
Iwasaki, Hiromi
Kuroda, Junya
Maeda, Takahiro
Shibayama, Hirohiko
Sunami, Kazutaka
Takamatsu, Hiroyuki
Tamura, Hideto
Shinozaki, Tomohiro
Iida, Shinsuke
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S172 - S172

← 1 2 3 4 5 →